SAnxA1 displays longer-lasting inhibitory effects on PMN recruitment and inflammation in vivo. (A) Mice were treated intradermally with fMLF (100 pmol) and the reported doses of AnxA1 and SAnxA1. Four hours later, skin samples (5-mm biopsies) were harvested and assayed for MPO activity. MPO activity values in fMLF-treated skin sites were 350 ± 44 mU/mg of tissue (taken as 100% control). Data are mean ± SEM of 4 separate experiments with 3-7 mice/group. (B) Time course of λ-carrageenan-induced paw edema in mice locally treated with PBS (50 μL), AnxA1 (1 μg), or SAnxA1 (1 μg). Values are mean ± SEM of 3 separate experiments with n = 6 mice per group. Representative images of the paw collected 24 hours after treatment. *P < .05 vs. vehicle group and #P < .05 versus respective AnxA1 group. (C) Hematoxylin and eosin staining of paw tissue samples collected 4 and 24 hours after λ-carrageenan in mice treated with either vehicle, AnxA1, or SAnxA1 as in panel B. Images are representative of analyses of tissue samples from 4 mice.